Resistance mechanisms are usually either on target; within the kinase domain itself, or off-target or bypass alterations, both of which are a concern for MKI use and selective RET kinase inhibitors utilized in MTC (Fig. 3). This evidence concerns the gene RET and medullary thyroid gland carcinoma.